Krystal Biotech (KRYS)

• Market cap: $4.91B
• 1 day: -3.75%
• 5 days: -15.58%
• 1 month: -4.33%
• 3 months: -11.98%
• 6 months: 4.63%
• Year to date: 36.64%
• 1 year: 71.49%
• 5 years: 231.15%
• 10 years: 1,504.70%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Employees: 229

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

184% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 19

34% more call options, than puts

Call options by funds: $89.7M | Put options by funds: $67.2M

17% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 88

15% more funds holding

Funds holding: 241 [Q2] → 276 (+35) [Q3]

5% less capital invested

Capital invested by funds: $5.36B [Q2] → $5.09B (-$265M) [Q3]

4.77% less ownership

Funds ownership: 102.19% [Q2] → 97.42% (-4.77%) [Q3]

14% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 6 (-1) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $206 21% upside
• Avg. target: $218 28% upside
• High target: $221 29% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

Citigroup Yigal Nochomovitz 48% 1-year accuracy 21 / 44 met price target	21% upside $206	Neutral Maintained	5 Nov 2024
HC Wainwright & Co. Joseph Pantginis 37% 1-year accuracy 124 / 331 met price target	29% upside $221	Buy Reiterated	5 Nov 2024
Stifel Dae Gon Ha 69% 1-year accuracy 9 / 13 met price target	29% upside $220	Buy Maintained	11 Sept 2024
HC Wainwright & Co. Joseph Pantginis 37% 1-year accuracy 124 / 331 met price target	29% upside $221	Buy Reiterated	29 Aug 2024
HC Wainwright & Co. Joseph Pantginis 37% 1-year accuracy 124 / 331 met price target	29% upside $221	Buy Maintained	28 Aug 2024